Novel anti-CD33 immunoconjugate demonstrating in vitro and in vivo activity against human acute myeloid leukemia (AML) cells.

被引：0
|
作者：
Hebib, Nadia C.
Larochelle, Fannie
Lutz, Bob
Lambert, John
Blattler, Walter
Roy, Denis Claude
机构：
[1] Hop Maisonneuve Rosemont Res Ctr, Montreal, PQ, Canada
[2] ImmunoGen Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5558
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Elimination of human acute myeloid leukemia (AML) cells using an anti-CD33 maytansinoid immunoconjugate
    Hebib, N. C.
    Larochelle, F.
    Lutz, B.
    Lambert, J.
    Hébert, J.
    Blattler, W.
    Roy, D. C.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 53 - 53
  • [2] Selective ablation of acute myeloid leukemia using an anti-CD33 calicheamicin immunoconjugate.
    Sievers, EL
    Appelbaum, FA
    Spielberger, RT
    Forman, SJ
    Flowers, DA
    Berger, MS
    ShannonDorcy, K
    Bernstein, ID
    BLOOD, 1997, 90 (10) : 2246 - 2246
  • [3] Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts
    Walter, Roland B.
    Boyle, Kelli M.
    Appelbaum, Frederick R.
    Bernstein, Irwin D.
    Pagel, John M.
    BLOOD, 2008, 111 (09) : 4813 - 4816
  • [4] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
    Stasi, Roberto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (04) : 527 - 540
  • [5] In Vivo efficacy of a novel anti-CD33 targeted thorium conjugate (TTC) in mouse models of acute myeloid leukemia (AML)
    Hagemann, Urs B.
    Borrebaek, Joergen
    O'Shea, Adam
    Wang, Ellen
    Wickstroem, Katrine
    Bjerke, Roger M.
    Karlsson, Jenny
    Ryan, Olav B.
    Cuthbertson, Alan
    CANCER RESEARCH, 2015, 75
  • [6] What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
    Jurcic, Joseph G.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (01) : 65 - 73
  • [7] What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
    Joseph G. Jurcic
    Current Hematologic Malignancy Reports, 2012, 7 : 65 - 73
  • [8] Targeting of the CD33-calicheamicin immunoconjugate mylotarg (CMA-676) in acute myeloid leukemia:: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
    van der Velden, VHJ
    te Marvelde, JG
    Hoogeveen, PG
    Bernstein, ID
    Houtsmuller, AB
    Berger, MS
    van Dongen, JJM
    BLOOD, 2000, 96 (11) : 112A - 112A
  • [9] ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR THERAPY FOR ACUTE MYELOID LEUKEMIA
    O'Hear, Carol
    Heiber, Joshua
    Geiger, Terrence
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S1 - S1
  • [10] Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
    O'Hear, Carol
    Heiber, Joshua F.
    Schubert, Ingo
    Fey, Georg
    Geiger, Terrence L.
    HAEMATOLOGICA, 2015, 100 (03) : 336 - 344
12345